CHINOOK THERAPEUTICS INC (KDNY) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:KDNY • US16961L1061

40.39 USD
+0.09 (+0.22%)
At close: Aug 10, 2023
40.32 USD
-0.07 (-0.17%)
After Hours: 8/10/2023, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

KDNY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While KDNY has a great health rating, there are worries on its profitability. KDNY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year KDNY has reported negative net income.
  • KDNY had a negative operating cash flow in the past year.
KDNY Yearly Net Income VS EBIT VS OCF VS FCFKDNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • The profitability ratios for KDNY are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KDNY Yearly ROA, ROE, ROICKDNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

  • KDNY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KDNY Yearly Profit, Operating, Gross MarginsKDNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • KDNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KDNY has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for KDNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KDNY Yearly Shares OutstandingKDNY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
KDNY Yearly Total Debt VS Total AssetsKDNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

  • KDNY has an Altman-Z score of 10.57. This indicates that KDNY is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 10.57, KDNY belongs to the best of the industry, outperforming 88.27% of the companies in the same industry.
  • KDNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.57
ROIC/WACCN/A
WACC9.21%
KDNY Yearly LT Debt VS Equity VS FCFKDNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 5.82 indicates that KDNY has no problem at all paying its short term obligations.
  • KDNY has a Current ratio (5.82) which is in line with its industry peers.
  • A Quick Ratio of 5.82 indicates that KDNY has no problem at all paying its short term obligations.
  • KDNY has a Quick ratio (5.82) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.82
Quick Ratio 5.82
KDNY Yearly Current Assets VS Current LiabilitesKDNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • KDNY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.06%.
  • KDNY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -89.24%.
  • Measured over the past years, KDNY shows a very negative growth in Revenue. The Revenue has been decreasing by -18.69% on average per year.
EPS 1Y (TTM)-107.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.1%
Revenue 1Y (TTM)-89.24%
Revenue growth 3Y-29.19%
Revenue growth 5Y-18.69%
Sales Q2Q%141.15%

3.2 Future

  • Based on estimates for the next years, KDNY will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.12% on average per year.
  • Based on estimates for the next years, KDNY will show a very strong growth in Revenue. The Revenue will grow by 133.00% on average per year.
EPS Next Y-13.68%
EPS Next 2Y-10.56%
EPS Next 3Y0.56%
EPS Next 5Y17.12%
Revenue Next Year-50.48%
Revenue Next 2Y50.65%
Revenue Next 3Y140.24%
Revenue Next 5Y133%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KDNY Yearly Revenue VS EstimatesKDNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
KDNY Yearly EPS VS EstimatesKDNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • KDNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KDNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KDNY Price Earnings VS Forward Price EarningsKDNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KDNY Per share dataKDNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.56%
EPS Next 3Y0.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for KDNY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CHINOOK THERAPEUTICS INC

NASDAQ:KDNY (8/10/2023, 8:00:03 PM)

After market: 40.32 -0.07 (-0.17%)

40.39

+0.09 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07
Earnings (Next)11-08
Inst Owners0%
Inst Owner Change0%
Ins Owners4.24%
Ins Owner Change0%
Market Cap2.90B
Revenue(TTM)5.85M
Net Income(TTM)-245.65M
Analysts72.94
Price Target41.11 (1.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.1%
Min EPS beat(2)-13.35%
Max EPS beat(2)-4.85%
EPS beat(4)0
Avg EPS beat(4)-14.99%
Min EPS beat(4)-30.05%
Max EPS beat(4)-4.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)479.25%
Min Revenue beat(2)311.77%
Max Revenue beat(2)646.73%
Revenue beat(4)4
Avg Revenue beat(4)928.11%
Min Revenue beat(4)311.77%
Max Revenue beat(4)2351.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.54%
PT rev (3m)8.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.34%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)300.54%
Revenue NY rev (3m)300.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 495.85
P/FCF N/A
P/OCF N/A
P/B 8.12
P/tB 9.77
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.42
OCFYN/A
SpS0.08
BVpS4.97
TBVpS4.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.82
Quick Ratio 5.82
Altman-Z 10.57
F-Score2
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)43.03%
Cap/Depr(5y)40.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-107.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.1%
EPS Next Y-13.68%
EPS Next 2Y-10.56%
EPS Next 3Y0.56%
EPS Next 5Y17.12%
Revenue 1Y (TTM)-89.24%
Revenue growth 3Y-29.19%
Revenue growth 5Y-18.69%
Sales Q2Q%141.15%
Revenue Next Year-50.48%
Revenue Next 2Y50.65%
Revenue Next 3Y140.24%
Revenue Next 5Y133%
EBIT growth 1Y-192.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.95%
EBIT Next 3Y-18.27%
EBIT Next 5Y25.02%
FCF growth 1Y-110.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.88%
OCF growth 3YN/A
OCF growth 5YN/A

CHINOOK THERAPEUTICS INC / KDNY FAQ

Can you provide the ChartMill fundamental rating for CHINOOK THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to KDNY.


What is the valuation status of CHINOOK THERAPEUTICS INC (KDNY) stock?

ChartMill assigns a valuation rating of 0 / 10 to CHINOOK THERAPEUTICS INC (KDNY). This can be considered as Overvalued.


What is the profitability of KDNY stock?

CHINOOK THERAPEUTICS INC (KDNY) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CHINOOK THERAPEUTICS INC?

The Earnings per Share (EPS) of CHINOOK THERAPEUTICS INC (KDNY) is expected to decline by -13.68% in the next year.